Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study
Kazuki Ohashi, Ikuko Takahashi-Iwata, Zhao Jieyu, Ken Sakushima, Ichiro Yabe, Katsuhiko Ogasawara · 2024
Read Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study by Kazuki Ohashi, Ikuko Takahashi-Iwata, Zhao Jieyu, Ken Sakushima, Ichiro Yabe, Katsuhiko Ogasawara (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11574910.txt.
Description
Kazuki Ohashi and co-authors count, in a 2024 study, whether Hokkaido has enough clinics able to give a new Alzheimer's drug. Lecanemab was approved in Japan in 2023, but it demands brain scans and close monitoring, so only some hospitals qualify. Using map data, the team sorted hospitals into three scenarios by how fully they met the treatment rules. Then they measured how much of the population could reach one within thirty, sixty, or one hundred twenty minutes.
Coverage swung widely with the rules. Under the most workable scenario it reached fifty-six, about seventy-four, and eighty-eight percent at the three travel times. The far north and south were worst served, while Sapporo was flagged as likeliest to overflow. The authors call for new treatment centers placed where access and capacity are thinnest.
Catalog record
| CREATOR | Kazuki Ohashi, Ikuko Takahashi-Iwata, Zhao Jieyu, Ken Sakushima, Ichiro Yabe, Katsuhiko Ogasawara |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |